Quick Answer
Emergent BioSolutions Inc. reported Total Revenue of $742.90 million for fiscal year 2025.
Emergent BioSolutions Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $742.90M -28.8% |
$1.04B -0.5% |
$1.05B -6.1% |
$1.12B -37.0% |
$1.77B +14.0% |
$1.56B +40.6% |
| Revenue (ASC 606) | $742.90M -28.8% |
$1.04B -0.5% |
$1.05B | — | — | $1.56B +40.6% |
| Net Income | — | -$190.60M +74.9% |
-$760.50M -259.4% |
-$211.60M -196.4% |
$219.50M -28.1% |
$305.10M +459.8% |
| Diluted EPS | — | -$3.60 +75.8% |
-$14.85 -251.9% |
-$4.22 -203.9% |
$4.06 -28.4% |
$5.67 +445.2% |
| Total Assets | — | $1.39B -23.8% |
$1.82B -42.4% |
$3.17B +7.0% |
$2.96B +2.6% |
$2.88B +23.9% |
| Cash and Equivalents | — | $99.50M -10.9% |
$111.70M -82.6% |
$642.60M +11.5% |
$576.10M -7.3% |
$621.30M +270.3% |
| Long-Term Debt | $589.70M -15.8% |
$700.00M +56.8% |
$446.50M -0.4% |
$448.50M -44.6% |
$809.40M -3.8% |
$841.00M +5.3% |
| Stockholders Equity | — | $482.80M -25.6% |
$649.30M -53.2% |
$1.39B -13.9% |
$1.61B +11.1% |
$1.45B +33.3% |
| R&D Expense | — | $70.70M -36.5% |
$111.40M -40.8% |
$188.30M -19.9% |
$235.20M +0.3% |
$234.50M +3.7% |
| Operating Income | — | -$108.70M +85.0% |
-$726.40M -327.3% |
-$170.00M -149.8% |
$341.40M -21.3% |
$433.80M +280.2% |
| Shares Outstanding | — | 54.30M +4.0% |
52.20M +4.2% |
50.10M -2.3% |
51.30M -3.4% |
53.10M +2.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $231.10M | -21.3% | +64.0% |
| Revenue (ASC 606) | September 30, 2025 | $231.10M | -21.3% | +64.0% |
| Net Income | September 30, 2025 | $51.20M | -55.4% | +526.7% |
| Diluted EPS | September 30, 2025 | $0.91 | -55.8% | +513.6% |
| Total Assets | September 30, 2025 | $1.46B | -1.1% | +3.1% |
| Cash and Equivalents | September 30, 2025 | $245.50M | +63.8% | -8.2% |
| Long-Term Debt | September 30, 2025 | $663.10M | +0.2% | -0.7% |
| Stockholders Equity | September 30, 2025 | $582.50M | +14.6% | +8.6% |
| R&D Expense | September 30, 2025 | $13.50M | -2.2% | +8.0% |
| Operating Income | September 30, 2025 | $76.50M | +18.6% | +4681.2% |
| Shares Outstanding | September 30, 2025 | 52.70M | -2.6% | -1.9% |
- Emergent BioSolutions Inc. reported Total Revenue of $742.90 million for fiscal year 2025.
- Emergent BioSolutions Inc. showed a decrease of -28.8% in Total Revenue compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Revenue (ASC 606) of $742.90 million for fiscal year 2025.
- Emergent BioSolutions Inc. showed a decrease of -28.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Net Income of -$190.60 million for fiscal year 2024.
- Emergent BioSolutions Inc. showed an increase of +74.9% in Net Income compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Diluted EPS of $3.60 per share (loss) for fiscal year 2024.
- Emergent BioSolutions Inc. showed an increase of +75.8% in Diluted EPS compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Total Assets of $1.39 billion for fiscal year 2024.
- Emergent BioSolutions Inc. showed a decrease of -23.8% in Total Assets compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Cash and Equivalents of $99.50 million for fiscal year 2024.
- Emergent BioSolutions Inc. showed a decrease of -10.9% in Cash and Equivalents compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Long-Term Debt of $589.70 million for fiscal year 2025.
- Emergent BioSolutions Inc. showed a decrease of -15.8% in Long-Term Debt compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Stockholders Equity of $482.80 million for fiscal year 2024.
- Emergent BioSolutions Inc. showed a decrease of -25.6% in Stockholders Equity compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported R&D Expense of $70.70 million for fiscal year 2024.
- Emergent BioSolutions Inc. showed a decrease of -36.5% in R&D Expense compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Operating Income of -$108.70 million for fiscal year 2024.
- Emergent BioSolutions Inc. showed an increase of +85.0% in Operating Income compared to the prior fiscal year.
- Emergent BioSolutions Inc. reported Shares Outstanding of 54.30 million shares for fiscal year 2024.
- Emergent BioSolutions Inc. showed an increase of +4.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: